Literature DB >> 21336107

Infectious complications in out-of-hospital cardiac arrest patients in the therapeutic hypothermia era.

Nicolas Mongardon1, Sébastien Perbet, Virginie Lemiale, Florence Dumas, Hélène Poupet, Julien Charpentier, Frédéric Péne, Jean-Daniel Chiche, Jean-Paul Mira, Alain Cariou.   

Abstract

OBJECTIVES: Infectious complications are frequently reported in critically ill patients, especially after cardiac arrest. Recent and widespread use of therapeutic hypothermia has raised concerns about increased septic complications, but no specific reappraisal has been performed. We investigated the infectious complications in cardiac arrest survivors and assessed their impact on morbidity and long-term outcome.
DESIGN: Retrospective review of a prospectively acquired intensive care unit database.
SETTING: A 24-bed medical intensive care unit in a French university hospital. PATIENTS: Between March 2004 and March 2008, consecutive patients admitted for management of resuscitated out-of-hospital cardiac arrest were considered. Patients dying within 24 hrs were excluded. All patients' files were reviewed to assess the development of infection.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of the 537 patients admitted after cardiac arrest, 421 were included and 281 patients (67%) presented 373 infectious complications. Pneumonia was the most frequent (318 episodes), followed by bloodstream infections (35 episodes) and catheter-related infections (11 episodes). When grouped together, Gram-negative bacteria were the most frequently isolated infectious germs (64%), but the main pathogen detected was Staphylococcus aureus (57 occurrences). Both application itself (83 vs. 73%; p = .02) and duration (1244 vs. 1176 mins; p = .05) of therapeutic hypothermia were significantly more frequent in infected patients. Infection was associated with increased mechanical ventilation duration (6 [2-9] vs. 3 [2-5.5] days; p < .001) and intensive care unit length of stay (7 [4-10] vs. 3 [2-7] days; p < .001). Nonetheless, there was no impact on intensive care unit mortality (174 [62%] vs. 92 [66%] patients; p = .45) or on favorable neurologic outcome (cerebral performance category 1-2, 102 [36%] vs. 47 [34%] patients; p = .58).
CONCLUSIONS: Infectious complications are frequent after cardiac arrest and may be even more frequent after therapeutic hypothermia. Despite increase in care costs, long-term and clinically relevant outcomes do not seem to be impaired. This should not discourage the use of therapeutic hypothermia in cardiac arrest survivors.

Entities:  

Mesh:

Year:  2011        PMID: 21336107     DOI: 10.1097/CCM.0b013e3182120b56

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  34 in total

1.  Therapeutic temperature management (TTM): post-resuscitation care for adult cardiac arrest, with recommendations from the National TTM Workgroup.

Authors:  Siew Hon Benjamin Leong; Enoch Chan; Benjamin Choon Heng Ho; Colin Yeo; Sennen Lew; Duu Wen Sewa; Shir Lynn Lim; Chee Wan Lee; Pow Li Chia; Tien Siang Eric Lim; Eng Kiang Lee; Marcus Eng Hock Ong
Journal:  Singapore Med J       Date:  2017-07       Impact factor: 1.858

2.  Therapeutic Hypothermia After Cardiac Arrest.

Authors:  Sunjeet S Sidhu; Steven P Schulman; John W McEvoy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-05

Review 3.  Use of hypothermia in the intensive care unit.

Authors:  Jesse J Corry
Journal:  World J Crit Care Med       Date:  2012-08-04

4.  Blood glucose level and outcome after cardiac arrest: insights from a large registry in the hypothermia era.

Authors:  Fabrice Daviaud; Florence Dumas; Nadège Demars; Guillaume Geri; Adrien Bouglé; Tristan Morichau-Beauchant; Yên-Lan Nguyen; Wulfran Bougouin; Frédéric Pène; Julien Charpentier; Alain Cariou
Journal:  Intensive Care Med       Date:  2014-03-25       Impact factor: 17.440

5.  Initial lactate and lactate change in post-cardiac arrest: a multicenter validation study.

Authors:  Michael W Donnino; Lars W Andersen; Tyler Giberson; David F Gaieski; Benjamin S Abella; Mary Anne Peberdy; Jon C Rittenberger; Clifton W Callaway; Joseph Ornato; John Clore; Anne Grossestreuer; Justin Salciccioli; Michael N Cocchi
Journal:  Crit Care Med       Date:  2014-08       Impact factor: 7.598

6.  Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest.

Authors:  David R Janz; Ryan D Hollenbeck; Jeremy S Pollock; John A McPherson; Todd W Rice
Journal:  Crit Care Med       Date:  2012-12       Impact factor: 7.598

7.  Predictors of external cooling failure after cardiac arrest.

Authors:  Sylvie Ricome; Florence Dumas; Nicolas Mongardon; Olivier Varenne; Jérôme Fichet; Frédéric Pène; Benjamin Zuber; Benoît Vivien; Julien Charpentier; Jean-Daniel Chiche; Jean-Paul Mira; Alain Cariou
Journal:  Intensive Care Med       Date:  2013-01-08       Impact factor: 17.440

Review 8.  In-hospital cardiac arrest: are we overlooking a key distinction?

Authors:  Ari Moskowitz; Mathias J Holmberg; Michael W Donnino; Katherine M Berg
Journal:  Curr Opin Crit Care       Date:  2018-06       Impact factor: 3.687

9.  Targeted temperature management after intraoperative cardiac arrest: a multicenter retrospective study.

Authors:  Anne-Laure Constant; Nicolas Mongardon; Quentin Morelot; Nicolas Pichon; David Grimaldi; Lauriane Bordenave; Alexis Soummer; Bertrand Sauneuf; Sybille Merceron; Sylvie Ricome; Benoit Misset; Cedric Bruel; David Schnell; Julie Boisramé-Helms; Etienne Dubuisson; Jennifer Brunet; Sigismond Lasocki; Pierrick Cronier; Belaid Bouhemad; Serge Carreira; Emmanuelle Begot; Benoit Vandenbunder; Gilles Dhonneur; Philippe Jullien; Matthieu Resche-Rigon; Jean-Pierre Bedos; Claire Montlahuc; Stephane Legriel
Journal:  Intensive Care Med       Date:  2017-02-20       Impact factor: 17.440

Review 10.  Therapeutic hypothermia for traumatic brain injury.

Authors:  L A Urbano; Mauro Oddo
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.